While in contrast to vehicle-treated T2DM group, PHF1 was decreased with Zonisamide treatment (Figure 4D), which suggests that Tau phosphorylation at Ser 396/404 was significantly decreased by Zonisamide treatment. This evidence concerns the gene MAPT and type 2 diabetes mellitus.